Kymera Therapeutics, Inc. Overview
Pro stress-test →Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. The company is pioneering targeted protein degradation (TPD) technology to address immunological diseases with a pipeline of oral degrader medicines.
Strategic Profile
Pro stress-test →The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with immunological conditions.
Competitive Landscape
Pro stress-test →Kymera operates in the targeted protein degradation (TPD) space alongside other PROTAC and degrader platform companies. The competitive landscape includes private and public biotech firms pursuing similar protein degradation approaches. Key differentiators include Kymera's oral small molecule approach and focus on immunological/inflammatory diseases, distinguishing it from competitors.
Industry Context
Kymera Therapeutics, Inc. operates in Biopharmaceutical - Targeted Protein Degradation (TPD).
Key facts
Founded: 2015 · Headquarters: Watertown, Massachusetts, US · Employees: 225 · Revenue: $47.1M · Market cap: $4.42B